This is a recording of a live webinar that took place on 13 November 2024. This recording will be available to view until 13 May 2025.
Chronic kidney disease (CKD) (stages 3-5) affects 1 in 10 people globally. The prevalence of CKD is rising due to an aging population and increasing numbers of people living with type 2 diabetes and hypertension, which are common causes of CKD. CKD is a significant risk factor for cardiovascular disease and CKD is associated with approximately 45,000 premature deaths in the UK each year.
Standard treatment for CKD consists of blood pressure control, use of ACE-inhibitors/ARBs, glycaemic management for those with diabetes and active lipid lowering therapy. Over recent years there have been significant advances in additional therapies, including SGLT2 inhibitors for cardio-renal protection in CKD, with evidence informing changes to guidelines and our management of CKD in primary care.
Learning objectives
- Appreciate the implications of renal complications for morbidity and mortality within the cardiorenal-metabolic system.
- Examine evidence for existing and newer treatment options for renoprotection in patients with CKD and diabetes.
- Review progression of national and international guidance for management of CKD as medical evidence has progressed.
- Understand the role of targeted anti-glycaemic treatment for people with CKD.
Webinar Chair:
Webinar Speakers:
- Dr Pauline Swift, Consultant Nephrologist and Associate Medical Director for Research and Education, Epsom and St Helier University Hospital NHS Trust
- Dr Kevin Fernando, GPwER Diabetes and medical education and RCGP Clinical Advisor for diabetes and multimorbidity
- Dr William Hinchfliffe, Consultant Nephrologist, South Tyneside and Sunderland NHS Foundation Trust
